How much does weight change with oral obesity treatment medication? Results from a 72-week study of 238 Japanese individuals

How much does weight change with oral obesity treatment medication? Results from a 72-week study of 238 Japanese individuals

To Australian Pharmacies: What's Changed with the "Oral Obesity Treatment"?

Once a week, self-inject. Or take a pill every day. Counting the number of times, injections are fewer. However, for those who hesitate multiple times before piercing their body with a needle, that once-a-week injection is no small burden.

On November 16 in Australia, the oral medication "Foundayo" (generic name orforglipron) by Eli Lilly was listed in the pharmaceutical register. It is a prescription drug used for chronic weight management in adults and the treatment of type 2 diabetes. The following day, on the 17th, the Australian newspaper 'The Age' reported that patients might be able to receive it from pharmacies within a few days. This was based on the supply outlook at the time, and the actual arrival date may vary by pharmacy.

In early November in Australia, Novo Nordisk's "Wegovy" was also approved as a tablet. The "second drug" refers to the number of oral medications that can be used for weight management in obesity, acting on GLP-1 receptors. Both require a doctor's prescription.


Even with the same "once a day," the morning routine differs

The difference between the two drugs becomes clear when you imagine the breakfast table. Wegovy tablets, which contain semaglutide, are taken in the morning on an empty stomach. On the other hand, Foundayo does not have specific restrictions on the time of day it is taken or on food and water intake. For those whose work hours vary by day or who eat breakfast immediately after waking, where to incorporate medication into their daily routine differs.

In Australia, those eligible for weight management with Foundayo are, in principle, adults with a BMI of 30 or higher at the start of treatment, or adults with a BMI of 27 to less than 30 who have at least one weight-related health issue. It is used in combination with improved diet and physical activity, including maintaining weight after weight loss. The news of it being available in pharmacies comes against the backdrop of long-term treatment.


In a trial with 238 Japanese participants, how much changed in 72 weeks

In Japan, the effectiveness of this drug for obese patients is also being studied. The phase 3 trial "ATTAIN-J" conducted at 16 domestic facilities involved 238 adults with obesity-related health disorders such as hypertension and dyslipidemia, who had not succeeded in losing weight through diet therapy. Participants were randomly divided into four groups and took one of three dosage levels of the drug or a placebo without active ingredients once a day.

After 72 weeks, the **average weight reduction rate from the start was 5.9%, 8.7%, and 7.9% for the three active drug groups, and 0.6% for the placebo group**. When considering the effect on individuals, another figure is also informative. The percentage of people who lost more than 5% of their initial weight was 46-61% in the active drug groups and 15% in the placebo group. Even among those who took the drug, there was a range in weight change.

Effects on health conditions were also recorded. Mild to moderate gastrointestinal symptoms were mainly observed in the active drug groups, and some stopped taking the medication due to nausea or vomiting. As of November 20, 2026, domestic approval in Japan has not been confirmed, and the prescription conditions and prices in Australia do not directly apply to Japan.


Divided Opinions on Social Media: "Which is Easier to Continue?"

In October, prior to the announcement in Australia, a post on the Reddit community for Foundayo users described feelings on injection days. The poster mentioned that it wasn't so much the needle itself that was frightening, but the moment they thought they had to inject themselves, they felt nauseous. Switching to pills for the first time, they were relieved not to have to inject on the usual injection day.

 

On the other hand, in another thread where UK users discussed weight maintenance, some expressed that the once-a-week injection was more convenient for them. They would consider switching if the pills became significantly cheaper, but they didn't see the benefit of increasing the daily hassle of taking medication.

Although these are individual experiences, comparing the two makes the questions to ask in the consultation room more concrete. Is the burden the moment of needle insertion, remembering to take medication daily, or the cost incurred with each prescription?


250 to 370 AUD for 30 days. The Cost Issue Beyond Approval

The recommended retail price for Foundayo in Australia, as indicated by Lilly, is 250 to 370 AUD for 30 days, depending on the dosage. Purchasing 30 days' worth at the same price 12 times would cost 3,000 to 4,440 AUD just for the medication. Because it's a long-term medication, this total cost might be closer to what patients consider than the price tag of a single box.

Diabetes Australia welcomed the option to choose pills but pointed out that drug approval and subsidies through the public pharmaceutical benefit scheme are separate procedures. The patient group questions whether people who could expect health improvements from treatment are being left behind due to their ability to pay.

For those who feel uneasy from the morning thinking about injection days, having the option to choose pills is meaningful. For those who have already integrated the once-a-week injection into their lives, there are reasons to continue it. In Australia, it's not just the variety of medications that has increased. There's now more room to consult with doctors on treatments that can be continued, considering effects, side effects, daily schedules, and household budgets.


Sources